Director/PDMR Shareholding

April 19, 2021
PDF Version
RNS Number : 8100V
Renalytix AI PLC
19 April 2021
 

 

Renalytix AI plc

 

Director/PDMR Shareholding

 

New York, 19 April 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announces that it has been advised of the transfer by James McCullough, the Company's Chief Executive Officer, of certain of the ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares") owned by him to a new family trust, The McCullough 2020 Irrevocable Trust (the "Trust").

 

The transaction involves the gift of 255,440 Ordinary Shares to James McCullough and Michele Wiles as investment trustees of the Trust and the sale of 2,298,958 Ordinary Shares to James McCullough and Michele Wiles as investment trustees of the Trust.

 

Following completion of this transfer, James McCullough remains interested in 2,870,110 Ordinary Shares representing 3.98% of the current issued share capital. 2,554,398 are held via the Trust with the balance of 315,712 being held in James McCullough's name.

 

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James McCullough

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Renalytix AI plc

b)

Legal Entity Identifier

213800NTOH3FK3WER551

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of £0.0025 each

 

 

ISIN Code: GB00BYWL4Y04

b)

Nature of the transaction

Gift of shares to a trust for nil consideration

Sale of shares to a trust

 

c)

Currency

N/A

d)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

255,440 Ordinary Shares



US$6.68

2,298,958 Ordinary Shares




e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

- Aggregated volume

- Price

- Aggregated total

 

255,440

Nil

Nil

 

2,298,958

$6.68

US$15,357,039.44

 

f)

Date of the transaction

18 April 2021

g)

Place of the transaction

Outside a trading venue

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR



Stifel (Nominated Adviser, Joint Broker )

Tel: 020 7710 7600

Alex Price / Nicholas Moore




Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams




Walbrook PR Limited

Tel: 020 7933 8780 or  renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303




 

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally.  The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer.  Every day, 13 patients in the United States die while waiting for a kidney transplant.

 

*  https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKFBDDBKBPQD